Dr
Vincent
Van Der Mark

Trainee Patent Attorney

The Hague Office

Chemistry

Telephone. +31(0) 70 240 0899
Email. [email protected]

Experience

Vincent graduated with a MSc degree in Medical Biology from the University of Amsterdam, where he also obtained a PhD in Biochemistry. His doctoral research focused on the phospholipid flippase ATP8B1 and its role in intracellular trafficking. This work resulted in three first-authored experimental publications in highly-ranked scientific journals.

Following this Vincent continued to work in academia as a post-doctoral researcher in the Academic Medical Center in Amsterdam. Using direct input from the pharmaceutical industry he developed and studied several cell culture systems that can act as models for drug metabolism and toxicity testing. He also became the main inventor on a patent application for a new improved liver cell line with potential use in a bio-artificial liver system.

Vincent went on to work as an analyst in the Healthcare team of M Ventures, the corporate venture capital arm of Merck KGaA, where he performed due diligence on technical, commercial and patented features of new investment proposals in the fields of (immuno-)oncology and immunology.

Prior to joining HGF, Vincent worked in the technology transfer office of the University of Leiden, specifically at the Leiden University Medical Center. Here, his roles included scouting for new (patentable) inventions, IP management, business development, advising on start-ups and investments, licencing and research agreements. During this time he came into contact with many cutting-edge technologies in the field of medical devices, diagnostic methods, software applications, antibodies, and cancer neoepitopes.

At HGF Vincent gained ample experience with patenting agrochemicals and various other subjects that combine chemistry and biology.

Qualifications

Trainee


MSC

Medical Biology

PHD

Biochemistry

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.